It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US.

The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.

Humulin N is a type of insulin used to treat type 1 and type 2 diabetes. Get the facts and see if this drug may work for you.